Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyBlue Cross Blue Shield Nebraska intracameral impla…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - NebraskaPolicy I.219

    Intracameral Implants (Requires Preauthorization)

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Nebraska Policy I.219 alerts

    Get alerted when Policy I.219 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governing preauthorization and medical necessity criteria for one-time intracameral drug-eluting implants (bimatoprost/Durysta and travoprost/iDose TR) to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

    Policy Summary
    PayerBlue Cross Blue Shield - Nebraska
    PolicyIntracameral Implants (Requires Preauthorization)
    Policy CodePolicy I.219
    Change TypeNo material change
    Effective DateJun 1, 2026
    Last ReviewMar 1, 2027
    Next Review DateFeb 3, 2027
    Key ActionObtain preauthorization and document patient age, prior trials and failures or intolerance to at least one topical prostaglandin and one topical beta-blocker, planned eye, prior same-product treatment, and per-eye dose.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2named products covered
    10 mcgDurysta max dose
    75 mcgiDose TR max dose
    18+minimum age

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria for Intracameral Implants

    Durysta (bimatoprost) — Covered when ALL criteria are met

    One-time intracameral injection (bimatoprost (Durysta)) may be scientifically validated when ALL the following are met:

    Durysta coverage criteria: A. Patient is 18 years of age and older; AND B. Patient has tried and failed or has intolerance to at least one topical ophthalmic prostaglandin (e.g., bimatoprost, latanoprost, travoprost); AND C. Patient has tried and failed or has intolerance or contraindication to at least one topical beta-adrenergic blocker (betaxolol, metipranolol, timolol); AND D. The injection or implant will only be administered to the affected eye; AND E. The affected eye has not received prior treatment with bimatoprost (Durysta); AND F. The dose does not exceed 10 mcg bimatoprost per affected eye.

    All items are required

    iDose TR (travoprost) — Covered when ALL criteria are met

    One-time intracameral implant (travoprost (iDose TR)) may be scientifically validated when ALL the following are met:

    iDose TR coverage criteria: A. The patient is 18 years of age and older; AND B. The patient has tried and failed or has intolerance to at least one topical ophthalmic prostaglandin (e.g., bimatoprost, latanoprost, travoprost); AND C. The patient has tried and failed or has intolerance or contraindication to at least one topical beta-adrenergic blocker (betaxolol, metipranolol, timolol); AND D. The injection or implant will only be administered to the affected eye; AND E. The affected eye has not received prior treatment with travoprost (iDose TR); AND F. The dose does not exceed 75 mcg travoprost per affected eye.

    All items are required

    All other indications for intracameral drug-eluting implants that are not specifically listed as covered with criteria (Durysta or iDose TR) are considered investigational.

    When the specified product-specific medical necessity criteria for intracameral implants are not met, the requested services are considered investigational.

    Coding and Dose Limits

    CPT4 codesCPT
    0660TIMPLTJ ANT SGM IO NBIODEGRADABLE RX ELUTING SYS
    0661TRMVL&RIMPLTJ ANT SGM IO NBIODGRD RX ELUT IMPLT
    HCPCS codesHCPCS
    J7351Inj bimatoprost itc imp1mcg
    J7355Inj travoprost intra impl
    inv-07: Bimatoprost (Durysta) per-eye dose — numeric limit
    Maximum per-eye dose10 mcg bimatoprost per affected eye
    ProductDurysta (bimatoprost)
    Use limitationOne-time intracameral injection per affected eye
    inv-08: Travoprost (iDose TR) per-eye dose — numeric limit
    Maximum per-eye dose75 mcg travoprost per affected eye
    ProductiDose TR (travoprost)
    Use limitation

    Preauthorization, Documentation, and Denial Triggers

    Prior Authorization

    Preauthorization required for intracameral implants

    Preauthorization is required for intracameral implants; coverage is available only when all product-specific medical necessity criteria are met.

    • Applicable CPT/HCPCS: 0660T, 0661T, J7351, J7355 (see coding section).
    Step Therapy

    Prior medication trials required

    Prior therapeutic trials are required: the patient must have tried and failed or be intolerant/contraindicated to at least one topical ophthalmic prostaglandin AND at least one topical beta-adrenergic blocker before implantation.

    • Examples of topical prostaglandins: bimatoprost, latanoprost, travoprost.
    • Examples of topical beta-adrenergic blockers: betaxolol, metipranolol, timolol.

    Definitions

    inv-14: Intracameral implant — definition and brief description
    DefinitionA sterile, sustained-release drug delivery device placed within the anterior chamber of the eye to provide localized therapeutic effect over an extended period (may be biodegradable or non-biodegradable)
    Typical useDelivered at the time of or following intraocular surgery to provide consistent, low-dose medication directly to intraocular tissues
    Clinical intentReduces peak-trough variability, minimizes systemic exposure, and may improve adherence compared with topical therapies

    Background

    Intracameral implants are sterile, sustained-release drug delivery devices placed in the anterior chamber of the eye to provide localized, extended therapeutic effect aimed at reducing intraocular pressure with reduced systemic exposure and improved adherence. These devices may be biodegradable or non-biodegradable and are designed for single-administration placement to deliver prostaglandin-class medication directly to the target eye.

    Durysta (bimatoprost) is a biodegradable intracameral implant FDA-approved as a single administration option to lower intraocular pressure in adults with open-angle glaucoma or ocular hypertension; iDose TR (travoprost) is an intracameral travoprost implant that received FDA single‑administration approval with demonstrated early intraocular pressure reduction in clinical studies. Use is subject to product‑specific coverage criteria and preauthorization.

    Revision History

    2026-06-01Original effective date

    Policy became effective on 2026-06-01.

    2026-02-04Last review

    Policy was last reviewed on 2026-02-04.

    2027-02-03Next reviewLatest

    Next scheduled review date set for 2027-02-03.

    Policy Summary
    PayerBlue Cross Blue Shield - Nebraska
    PolicyIntracameral Implants (Requires Preauthorization)
    Policy CodePolicy I.219
    Change TypeNo material change
    Effective DateJun 1, 2026
    Last ReviewMar 1, 2027
    Next Review DateFeb 3, 2027
    Key ActionObtain preauthorization and document patient age, prior trials and failures or intolerance to at least one topical prostaglandin and one topical beta-blocker, planned eye, prior same-product treatment, and per-eye dose.
    SourceLink
    On This Page
    Coverage Criteria for Intracameral ImplantsCoding and Dose LimitsPreauthorization, Documentation, and Denial TriggersDefinitionsBackgroundRevision History
    One-time intracameral implant per affected eye
    Documentation Required

    Required documentation for preauthorization

    Documentation submitted for preauthorization must demonstrate patient age, prior trial and failure or intolerance/contraindication to at least one topical prostaglandin and one topical beta-adrenergic blocker, that the implant will be administered only to the affected eye, no prior same-product treatment to the affected eye, and that the planned dose does not exceed the product-specific per-eye maximum.

    • Age: patient is 18 years of age or older.
    • Prior treatments: details of trials, failures, or intolerance/contraindication to prostaglandin and beta-blocker therapies.
    • Eye-specific details: confirmation the procedure is for the affected eye and that the affected eye has not previously received the same product (Durysta or iDose TR).
    • Dose: planned dose must not exceed 10 mcg bimatoprost per eye (Durysta) or 75 mcg travoprost per eye (iDose TR).
    Denial Risk

    Denial triggers for medical necessity

    Request may be denied if the intracameral implant does not meet ALL specified criteria for the named product, including age ≥18, required prior medication trials/intolerance, eye-specific use, no prior same-product treatment to the affected eye, and adherence to per-eye dose limits.

    • Durysta denial triggers include prior treatment of the affected eye with bimatoprost or dose exceeding 10 mcg per eye.
    • iDose TR denial triggers include prior treatment of the affected eye with travoprost (iDose TR) or dose exceeding 75 mcg per eye.
    • Requests not meeting the required prior trials or for indications other than open-angle glaucoma or ocular hypertension are considered investigational.